A new oncolytic V accinia virus augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery.

Jahangir AhmedLouisa S ChardMing YuanJiwei WangAnwen HowellsYuenan LiHaoze LiZhongxian ZhangShuangshuang LuDongling GaoPengju WangYongchao ChuChadwan Al YaghchiJoel SchwartzGhassan AlusiNicholas LemoineYaohe Wang

Published in: Journal for immunotherapy of cancer (2021)

These data provide a proof of concept for translation of the regime into clinical trials. VVΔTKΔN1L-IL12 is a promising agent for use as an adjuvant to surgical treatment of solid tumors.

Keyphrases

clinical trial
immune response
early stage
electronic health record
big data
phase ii
dendritic cells
open label
inflammatory response